Applications of 5-(4-Amino-2-Oxo-1(2H)-Pyrimidinyl)-1,3-Oxathiolane-2-Carboxylic Acid 5-Methyl-2-(1-Methylethyl)Cyclohexyl Ester in Industrial Manufacturing

As an established manufacturer of advanced nucleoside intermediates, we supply 5-(4-Amino-2-Oxo-1(2H)-Pyrimidinyl)-1,3-Oxathiolane-2-Carboxylic Acid 5-Methyl-2-(1-Methylethyl)Cyclohexyl Ester to specialized sectors requiring rigorous quality and traceability. Our material supports demanding downstream processes in regulated industries where precise specification and consistent impurity control define production success. The following industrial applications demonstrate how this intermediate fits stringent workflows from pharmaceutical synthesis to life science reagents.

1. Antiviral Nucleoside Active Pharmaceutical Ingredient (API) Synthesis

Leading pharmaceutical manufacturers employ this intermediate in the synthesis of key nucleotide analog APIs designated for oral antiviral therapies, with focus on second-generation prodrugs. The compound enters process stages after C-5 pyrimidine modifications but before full prodrug conjugation. Strict adherence to pharmacopeial grade and quantifiable impurity thresholds is essential due to the downstream use in direct human therapeutics.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP & EP monographs: Nucleoside analogues category (where applicable)
• FDA 21 CFR Part 211: Pharmaceutical GMPs
• Data integrity guidelines for batch record and in-process control (FDA/EMA)

Typical usage ratio

• 0.95-1.05 molar equivalent per target API batch, adjusted by route yield, byproduct profile, and process scale

Downstream process integration

• Reaction introduction at nucleoside coupling or phosphorylation stage in solid or solution-phase synthesis routes
• Purification through preparative chromatography to remove process impurities prior to API intermediate isolation

Final product types

• Finished nucleotide analog API for direct pharmaceutical formulation
• Tablet and capsule dosage forms containing modified pyrimidine rings
• Bulk API for contract manufacturing of antiviral medications

2. Oligonucleotide Synthesis for Genetic Diagnostic Reagents

Manufacturers in the molecular diagnostics sector rely on this intermediate as a specialized building block in automated phosphoramidite oligonucleotide synthesis. Its presence facilitates enhanced hybridization properties and strand stability in probe and primer products—critical for high sensitivity PCR and gene sequencing applications under clinical laboratory accreditation.

Industry compliance standards

• ISO 13485:2016 – Medical devices quality management (for diagnostic reagents)
• Clinical and Laboratory Standards Institute (CLSI) MM13 – Verification of molecular assays
• US FDA 21 CFR Part 820: Quality System Regulation (applicable to diagnostic device components)
• Laboratory Developed Test (LDT) controls under CLIA

Typical usage ratio

• 0.2–2% w/w in automated solid-phase DNA synthesis columns, optimization per base incorporation sequence

Downstream process integration

• Integration during custom phosphoramidite loading and controlled-pore glass (CPG) attachment for automated DNA synthesizers
• Subsequent deprotection and purification steps performed using high-performance liquid chromatography (HPLC)

Final product types

• Real-time PCR primers/probes for viral and oncogene diagnostics
• Sequencing-grade oligonucleotides for clinical genomics and forensic workflows
• Labeled nucleic acid probes for fluorescence in situ hybridization (FISH) kits

3. Chemical Synthesis of Modified RNA Therapeutics

Advanced RNA drug developers utilize this compound in the site-specific incorporation of modified nucleotides during the preparation of synthetic single-stranded RNAs, aiming to modulate in vivo stability and immunogenicity. Integration occurs at the precursor step in scale-up oligoribonucleotide reactors governed by GMP bioprocessing protocols.

Industry compliance standards

• EU GMP Annex 2: Manufacture of biological medicinal substances
• US Pharmacopeia General Chapter <1045> Biotechnology-derived articles
• EMA/CHMP guidelines on RNA-based drug substances
• Sterility tests per USP <71> or Ph. Eur. 2.6.1

Typical usage ratio

• 1–5% molar incorporation, based on total nucleotide units per oligonucleotide strand; precise proportion determined by desired chemical modification profile

Downstream process integration

• Activation and coupling to other ribonucleotide phosphoramidites on a solid-phase synthesizer under controlled temperature and humidity
• Subsequent cleavage, deprotection, desalting, and QC via capillary electrophoresis and mass spectrometry

Final product types

• siRNA duplexes for RNA interference therapeutics
• Guide RNAs for CRISPR systems
• Messenger RNA (mRNA) strands with enhanced pharmacokinetics for gene therapy

4. Reference Material Production for Analytical and Quality Control Laboratories

Certified standards and research reagent companies use this compound to create reference materials, calibration solutions, and positive controls for analytical method validation in regulated pharmaceutical and academic laboratory settings. Stringent purity testing and accurate structural confirmation ensure reliability for high-sensitivity detection techniques.

Industry compliance standards

• ISO 17034:2016 – General requirements for the competence of reference material producers
• ISO/IEC 17025 – Testing and calibration laboratory accreditation
• USP General Chapter <11> on Reference Standards
• Traceability requirements under the International Laboratory Accreditation Cooperation (ILAC)

Typical usage ratio

• 0.1–0.5 mg/mL in standard reference material preparations; final concentration validated per target instrument detection limits

Downstream process integration

• Dissolution in ultrapure solvents followed by sterile filtration and ampoule filling
• Quantitative NMR and HPLC analysis for batch certification and assignment of true value

Final product types

• Pharmaceutical reference standards for HPLC and LC-MS/MS validation
• Analytical calibrators and positive controls for nucleoside detection assays
• Internal standards for bioanalytical method development labs